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The degree of damage to DNA following ifosfamide (IFO) treatment may be linked to the therapeutic efficacy. The pharmacokinetics
and metabolism of IFO were studied in 19 paediatric patients, mostly with rhabdomyosarcoma or Ewings sarcoma. Ifosfamide was
dosed either as a continuous infusion or as fractionated doses over 2 or 3 days. Samples of peripheral blood lymphocytes were
obtained during and up to 96h after treatment, and again prior to the next cycle of chemotherapy. DNA damage was measured
using the alkaline COMET assay, and quantified as the percentage of highly damaged cells per sample. Samples were also taken for the
determination of IFO and metabolites. Pharmacokinetics and metabolism of IFO were comparable with previous studies. Elevations in
DNA damage could be determined in all patients after IFO administration. The degree of damage increased to a peak at 72h, but had
returned to pretreatment values prior to the next dose of chemotherapy. There was a good correlation between area under the
curve of IFO and the cumulative percentage of cells with DNA damage (r
2¼0.554, P¼0.004), but only in those patients receiving
fractionated dosing. The latter patients had more DNA damage (mean7s.d., 27367597) than those patients in whom IFO was
administered by continuous infusion (14537730). The COMET assay can be used to quantify DNA damage following IFO therapy.
Fractionated dosing causes a greater degree of DNA damage, which may suggest a greater degree of efficacy, with a good correlation
between pharmacokinetic and pharmacodynamic data.
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Ifosfamide (IFO) is used in the treatment of a variety of paediatric
tumours, especially sarcomas, and is usually combined with a
number of different agents such as vincristine, actinomycin D or
doxorubicin (Carli et al, 2003). Although it is considered to be an
analogue of cyclophosphamide, IFO appears to have specific
activity in some tumour types, for example, rhabdomyosarcoma
(Breneman et al, 2003). Like cyclophosphamide, IFO requires
metabolic activation, mediated by cytochrome P450 enzymes
(Walker et al, 1994), initially forming a 4-hydroxy metabo-
lite, which spontaneously releases the active form – isophos-
phoramide mustard (IPM). Competing pathways for IFO
metabolism result in inactive, dechloroethylated metabolites
(2-dechloroethylifosfamide (2DCI) and 3-dechloroethylifosfamide
(3DCI)) (Kerbusch et al, 2001a). In addition, up to 20% of a dose
of IFO can be recovered unchanged in the urine. So, in contrast
to cyclophosphamide where 90% of a dose is activated, as
much as 70% of a dose of IFO may be eliminated by inactivating
pathways. An intermediate on the activation pathway is also
subject to metabolic inactivation, aldoifosfamide being further
oxidised to an inactive carboxy form by aldehyde dehydrogenases
(Dockham et al, 1992).
The cytotoxic effect of IFO is thought to be mediated by the
reaction of IPM, via unstable aziridine intermediates, with
nucleophilic bases of DNA (Sladek, 1988). As a bifunctional
alkylating agent, IFO is able to form inter- and intrastrand
crosslinks, as well as crosslinks between DNA and protein.
Previous studies have shown that the DNA damage caused by
IFO in its activated form is detectable by COMET analysis
(Johnstone et al, 2000). This method, also known as single-cell
gel electrophoresis, determines the degree of fragmentation of
DNA caused by a particular agent under alkali or neutral
conditions (Fairbairn et al, 1995; Rojas et al, 1999). COMET
analysis of the IFO-induced DNA damage has been applied to
MCF-7 breast cancer cells in vitro and to peripheral blood
lymphocytes (PBL) and breast tumour cells from patients
(Johnstone et al, 2000). Another application of COMET to the
analysis of IFO DNA interactions is the detection of crosslink
formation, as these retard DNA migration after exposure of PBL to
ionising radiation (Hartley et al, 1999).
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sIn paediatric patients, the metabolism and pharmacokinetics of
IFO have been extensively studied (Boddy et al, 1993, 1995b; Silies
et al, 1998; Kerbusch et al, 2001a–c; Misiura et al, 2003). No direct
correlation has been found between pharmacokinetic parameters
of drug or metabolites and clinical outcome (Kerbusch et al,
2001d). It may, therefore, be appropriate to consider an
intermediate measure of IFO action such as the degree of DNA
damage in PBL. In the current study, PBL from 19 patients have
been collected at various times after IFO administration. Data from
COMET analysis has been compared to pharmacokinetic para-
meters. In addition, COMET analysis of DNA damage in vitro has
been performed, to investigate the relationship between DNA
damage and antiproliferative effect.
PATIENTS AND METHODS
Ifosfamide and its metabolites were the kind gift of Dr Ju ¨rg Pohl,
ASTA Medica, Germany. All other reagents were obtained from
Sigma, Poole, Dorset, UK, except where otherwise indicated, and
were of an appropriate analytical grade.
In all, 19 patients (five female) aged between 2 and 19 years were
recruited to the study. In each case, informed written consent was
obtained from the patient and/or parent, as appropriate, and the
study was approved by the ethical committee of the Newcastle
Hospitals Trust. Details of patient characteristics, including the
protocol that the patients received, IFO dose and schedule are
given in Table 1. Of these patients, eight were studied after a
second dose of IFO in order to assess the degree of intersubject
variability in DNA damage. Treatment was the same on the two
courses studied.
Ifosfamide was administered either as a continuous infusion
over 3 days (n¼8) or as a 3h infusion every 24h for 3 days
(n¼5). Three patients were treated with just 2 consecutive days of
fractionated dosing and three received 3 consecutive days of IFO,
but with a 1h infusion time. No attempt was made to control
concurrent medication, but a record was kept of potential
interacting drugs (Table 1).
For those patients receiving a 3h infusion of IFO, blood samples
were taken for the determination of IFO and its metabolites before
administration, then at 1.5 and 3h during the infusion and at 0.5,
1, 2, 4, 6 12 and 24h after the end of infusion. Patients with a 1h
infusion had a pretreatment and end of infusion samples taken
together with the postinfusion samples as for a 3h infusion.
Sampling was repeated for each day of drug administration. For
those patients receiving a continuous infusion of IFO, sample
times were pretreatment, 3, 6, 12, 18, 24, 36, 48, 60 and 72h during
the infusion. Samples were also taken at 2, 4, 6, 12, 18 and 24h
after the end of the infusion.
Plasma was separated by centrifugation at 1500g and stored
frozen at  201C until subsequent analysis. Ifosfamide, 2DCI, 3DCI
and carboxyifosfamide were determined by a validated high-
performance thin-layer chromatography method (Boddy and Idle,
1992). A minor metabolite, 4-ketoifosfamide, was detected in some
patients, but could not be consistently quantified. Noncompart-
mental methods were used to estimate pharmacokinetic para-
meters for parent drug as described previously (Boddy et al,
1995b), and the linear trapezoidal rule was used to calculate area
under the curve (AUC) for parent drug and metabolites. Area
under the curve values for the continuous infusion data relate to all
3 days of administration, including data after the end of infusion.
In addition to samples collected for pharmacokinetic analysis,
whole blood samples were taken prior to treatment, and at 3 and
24h after each dose. A final sample was taken prior to the next
course of treatment, that is, 3 weeks after the start of the initial
course. The sampling times were based on previous data
Table 1 Patient details
Patient
number Sex
Age
(years) Diagnosis
Course
studied
Course
type
Ifosfamide
dose (gm
 2) Other medication
1M 2 R M 3 I E 1 9 Imi, ond, tei
2F 3 R M 4 I E 1 9 acy, cot, flu, fru, ond
3 M 10 HE 1 IE1 9 Cot, ond, par
4 M 17 RM 1 IE1 9 Chl, dex, gav, fru, ond, par, sen, tem
5 M 5 RM 5 IVA1 9 Cep, chh, dex, lac, tri
6 F 2 RM 3 IVA1 9 Chh, dex, ond, tri
7 M 19 MFH 1 IE1 9 Dih, flu, fru, imi, lac, nab, ond,
8 F 15 ES 4 IVA3 6 Dex, flu, lac, mor, nab, ond, ran
9 M 4 RM 2 IVA1 9 Dex, ond
10 M 19 PNT 4 IE1 9 Ami, cod, cyc, dex, flu, gav, imi, met, ran, sen,
sep, tei, tem
11 M 6 RM 4 IVA2 6 Cep, fru, ond, lor, mtp, ond
12 F 3 RM 3, 6 IVE 9 Dex, ond
13 M 19 RM 5, 9 IVE 9 Ami, car, cod, dex, met, ond mbl cla
14 M 19 OS 2, 3 IE2 9 Dex, lac, met, ond
15 M 15 OS 2, 4 IE2 9 Dex, met, ond
16 M 19 ES 3, 5 IVAd 6 Cyc, dex, met, ond
17 M 7 RM 2, 4 IVA2 6 Car, cod, cyc, lac, ond
18 M 10 ES 2, 4 IVA3 6 Dex, ond, cyc, dex, lor, met
19 F 3 RM 3, 4 IVA2 6 Dex, met, ond, ran, par
Diagnosis:E S¼Ewings sarcoma; HE¼haemangioendothelioma; MFH¼malignant fibrous histiocytoma; PNT¼primitive neuroectodermal tumour; OS¼osteogenic sarcoma;
RM¼rhabdomyosarcoma. Course type:I E 1 – ifosfamide 3gm
 2day
 1 continuous infusion over 3 days. Etoposide 200mgm
 2day
 1 as a 2h infusion on 3 consecutive days. IE2 –
as IE1, etoposide 150mgm
 2day
 1.I V A 1 – ifosfamide 3gm
 2day
 1 as a 3h infusion on 3 consecutive days. Actinomycin D and vincristine both 1.5mgm
 2 bolus on day 1 only.
IVA2 –a sI V A 1, ifosfamide on 2 days only. IVA3 –a sI V A 1, ifosfamide 2gm
 2day
 1 1h infusion on 3 consecutive days. IVAd – as IVA3, but adriamycin 20mgm
 2day
 1 as a 6h
infusion on 3 consecutive days, no actinomycin D. IVE – ifosfamide 3gm
 2day
 1 as a 3h infusion, etoposide 150mgm
 2 as a 4h infusion, each on 3 consecutive days. Vincristine
1.5mgm
 2 bolus on day 1 only. Other medication (drugs taken during study):A c y¼acyclovir; amy¼amitriptyline; car¼carbamazepine; cep¼cephalexin; chh¼chloral hydrate;
chl¼chlorpromazine; cla¼clarithromycin; cod¼codeine phosphate; cot¼cotrimoxazole; cyc¼cyclozine; dex¼dexamethasone; dih¼dihydrocodeine; dox¼doxorubicin;
flu¼fluconazole; fru¼frusemide; gav¼gaviscon; imi¼imipenem; lac¼lactulose; lar¼lorazepam; mbl¼methlyene blue; met¼metoclopropamide; mtp¼methotrimeprazine;
mor¼morphine sulphate; nab¼nabilone; ond¼ondansetron; par¼paracetamol; ran¼ranitidine; sen¼senna; tei¼teicoplanin; tem¼temazepam; tri¼trimeprazine. Drugs
thought to inhibit CYP3A4 are shown in bold, drugs known to induce CYP3A4 are underlined. All patients were also hydrated with mesna at an equivalent dose to ifosfamide (2
or 3gm
 2day
 1 in 3l). This was administered as a continuous infusion throughout the course and for 12h after completion of the course.
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one course of treatment had a second set of blood samples taken
for pharmacokinetic and COMET analysis.
The COMET assay was performed as described previously
(Johnstone et al, 2000). Peripheral blood lymphocytes were
isolated at the time of blood sampling using Lymphoprep. Storage
of PBLs was at  801C, and analysis was always completed within 1
month of sampling. Stability studies indicated that there was no
change in the measurement of DNA damage using the COMET
assay during 1 month of sample storage. The degree of DNA damage
in a given patient sample or in vitro investigation was quanti-
fied by measuring the distributed tail moment (TM) in a minimum
of 30 cells per slide. Images were analysed using the COMOS image
analysis software (Biorad Laboratories, Hertfordshire, UK). The
TM data were log normalised and a logarithmic mean and
standard deviation (s.d.) determined. The number of highly
damaged (HD) cells (log TM more than 2 s.d. from the mean)
per sample was calculated. To estimate the overall degree of DNA
damage caused during a cycle of chemotherapy, the AUC of
percentage of HD cells (AUCHD) per sample plotted against time
was calculated. An internal standard of CCRF-CEM cells that had
received a standard dose of radiation was included as a control in
each COMET experiment.
In order to provide some background to the clinical studies, the
effect of IFO and its active metabolites on the formation of
COMET-detectable DNA damage in vitro was investigated. CCRF-
CEM leukaemia cells were exposed to varying concentrations of
the precursor of the active 4-hydroxy metabolite (4-hydroperox-
yifosfamide) or IPM for up to 72h, although these unstable
metabolites break down quickly in the medium. Growth inhibition
was determined by counting the cells using a Coulter counter and
was compared to the degree of DNA damage, as measured by the
COMET assay. AUCHD was determined by measuring the
percentage of HD cells at times 1, 24, 48 and 72h after the start
of drug exposure.
Statistical analysis was performed using Graphpad Prism,
version 3 (Graphpad, San Diego USA). Differences between
treatments were analysed using one-way analysis of variance and
relationships between pharmacokinetic parameters and DNA
damage measurements were analysed by linear regression.
RESULTS
Pharmacokinetics and metabolism of IFO
The pharmacokinetic parameters and AUC values for IFO and its
metabolites are given in Table 2. As reported previously (Boddy
et al, 1995b; Kerbusch et al, 2001c), apparent clearance is greater
in those patients receiving a continuous infusion (median
6.2lh
 1m
 2) compared to day 1 of fractionated dosing (median
4.1lh
 1m
 2). However, induction of metabolism is also apparent
on day 3 of the fractionated schedule with an increase in median
clearance from 4.1 to 6.1lh
 1m
 2. Correspondingly, the half-life
of IFO was longest after a single 3h infusion, and decreased with
repeated dosing or after a continuous infusion. The total AUC of
the parent drug was not different in those patients having
fractionated dosing over 3 days compared to those receiving a
continuous infusion and there was no difference in the AUCs of the
metabolites comparing the two groups. Although two patients
(Nos. 13 and 17) were being treated with the enzyme-inducing
anticonvulsant carbamazepine and four (Nos. 2, 7, 8 and 10) were
being treated with fluconazole, which may inhibit IFO metabolism,
none of these patients had remarkably high or low clearance
values. Similarly, plasma concentrations of metabolites were not
markedly different for these patients.
COMET analysis of DNA damage following IFO
administration
There was some variation in the degree of DNA damage present in
the pretreatment samples of patients receiving IFO for paediatric
malignancies. The median TM for all COMETs within an analysis
varied from 2 to 13 (arbitrary units), while the percentage of HD
cells varied from 1 to 13% of the total. There was no correlation
between the apparent amount of COMET-detectable DNA damage
and the number of prior courses of chemotherapy or the age of the
patient. The patient with the highest degree of pretreatment
damage was patient 16, who was a known cigarette smoker. The
effect of cigarette smoking on COMET-detectable DNA damage has
been noted previously (Hininger et al, 2004).
An increase in the degree of damaged DNA was apparent in
post-treatment samples from all patients studied (Figures 1A–F
and 2A–F). The COMETs and accompanying histograms clearly
show the evolution of DNA damage from pretreatment levels to the
maximum degree of DNA damage 72h after the start of
administration, for both 72-h infusion and fractionated dosing
over 3 days. In both cases, some degree of resolution of damage
was apparent 96h after the start of administration, and DNA
damage had returned to pretreatment values prior to the next
course of IFO.
The percentage of HD cells was chosen as a summary parameter
for the degree of DNA damage in each patient sample. Analysis
based on median TM or other measures of damage did not differ
qualitatively from that based on HD. Plots of percent HD against
time, superimposed on plasma concentration–time profiles, are
shown in Figures 3 and 4 for representative patients who received
either a continuous infusion or bolus administration, respectively.
Almost all patients showed an accumulation of HD DNA during
the time course of IFO administration, although for some patients
a degree of resolution between doses on a fractionated regimen
was apparent.
The relationship between overall DNA damage, as measured by
the area under the percentage HD DNA vs time curve (AUCHD)
and the pharmacokinetics of IFO, was explored. There was a strong
Table 2 Pharmacokinetics and metabolism of ifosfamide in the patients studied
Regimen N
IFO PK Metabolite AUCs (lMh)
Clearance
(lh
 1m
 2) t1/2 (h) Vd (lkg
 1) IFO CXI 3DCI 2DCI
72h CI 8 6.2 (2.6–7.4) 2.4 (1.3–5.6) 0.44 (0.16–1.82) 5135 (4668–13247) 941 (542–3443) 1868 (554–5342) 1166 (207–3011)
3 or 1h infusion day 1 11 4.1 (2.6–5.8) 4.7 (1.9–8.3) 0.89 (0.35–1.63) 6011 (4009–9488) 511 (47–1700) 1702 (521–3164) 1337 (326–2678)
3 or 1h infusion day 3 8 6.1 (3.0–7.8) 2.9 (2.0–4.6) 0.92 (0.53–1.33)
IFO-PK¼pharmacokinetic parameters for ifosfamide; t1/2¼half-life; Vd¼volume of distribution. For metabolite abbreviations see text. AUCs for IFO and metabolites in patients
receiving a fractionated dosing over 3 days are given cumulatively over the cycle of chemotherapy to allow for comparison with data from patients receiving the same dose as a
continuous 72h infusion (CI). AUCs are dose adjusted in those patients receiving only 2 days of therapy. Data have been combined for those patients receiving fractionated
doses of ifosfamide by either 1 or 3h infusion.
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spositive correlation between the AUCHD and the total AUC of IFO
when IFO was administered as a fractionated schedule over 2 or 3
days (Figure 5, r
2¼0.556, P¼0.004). There was also a moderate
correlation, in those patients receiving fractionated IFO, between
AUCHD and the AUC of the inactive carboxy metabolite (r
2¼0.49,
P¼0.023), but there was no other relationship between the
pharmacokinetics of IFO and COMET-detectable DNA damage.
Comparing DNA damage in PBL following IFO administration
using either a continuous infusion or 3-day fractionated adminis-
tration, it is clear that the latter regimen produces a higher
AUCHD (Figure 6). The difference between treatment schedules
was statistically significant (P¼0.0035, one-way ANOVA), if the
fractionated dosing data are restricted to those patients who
received 9gm
 2, the same dose as the continuous infusion
patients.
In those patients studied on more than one occasion, there was
good correlation between the AUCHD determined on the two
courses (r
2¼0.73). Also, there was no significant difference in the
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Figure 1 COMETs and histograms of tail moment (TM) for patient 14, course 2. Ifosfamide, 9gm
 2 fractionated over 3 days, was administered as a 72h
continuous infusion. Pairs of figures show COMETs and histograms (A) pretreatment, (B)2 4h ,( C)4 8h ,( D)7 2h ,( E) 96h and (F) 3 weeks after the start
of infusion.
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indication of cumulative damage or of changes in sensitivity to
treatment in successive courses (data not shown).
In vitro experiments with CCRF-CEM cells exposed to the active
metabolites of IFO (4-hydroxy-IFO and -IPM) showed that the IC50
for 4-hydroxy-IFO (19.671.5mM) was much lower than that of IPM
(256739mM). However, at an IC50 concentration, the AUCHD for
CCRF-CEM cells treated with either of the two agents were similar,
and comparable to those seen in PBL in patients receiving IFO
treatment (Table 3). Increasing the concentrations of the active
metabolites to 4 IC50 did not significantly elevate the AUCHD.
DISCUSSION
The role of IFO in treating paediatric malignancies has been the
subject of some controversy (Kamen et al, 1995; Carli et al, 2003).
As an alternative to cyclophosphamide, it seems to offer some
benefits in terms of antitumour effect, but only at the expense of a
wider spectrum of toxicity (Vela-Ojeda et al, 2000). While a great
deal of research has focused on the metabolism of IFO in relation
to side effects such as nephrotoxicity (Boddy et al, 1996) and
neurotoxicity (Wainer et al, 1994), relatively little is known
concerning the relationship between systemic pharmacology and
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Figure 1 (Continued).
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sthe drug interaction with its target, that is, DNA. Understanding of
such relationships is complicated by the fact that IFO is a prodrug.
While it would be more relevant to measure the degree of DNA
damage in the tumour, this is not practical in most clinical
scenarios and there are both ethical and technical problems
associated with such measurements. Peripheral blood lymphocytes
represent a nonproliferating surrogate tissue; however, PBLs do
allow for sequential measurements in the same patient and provide
a measure of the systemic exposure to DNA-damaging species.
We have previously applied this technique to breast cancer
patients being treated with IFO, but had only limited success
applying COMET analysis to tumour cells in fine-needle aspirates
(Johnstone et al, 2000). The COMET method used here detects
DNA strand breaks, presumably the result of repair processes or
resulting from denaturing of DNA during the method itself
(Rojas et al, 1999). Ifosfamide is thought to act by forming
interstrand crosslinks in DNA and a method has been developed
to use the COMET assay to measure such crosslinks directly
(Hartley et al, 1999). That method was not applied here as it was
not available at the start of the analysis and initial attempts to
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Figure 2 COMETs and histograms of tail moment (TM) for patient 9, course 2. Ifosfamide, 9gm
 2 fractionated over 3 days, was administered as a 3h
infusion each day. Pairs of figures show COMETs and histograms (A) pretreatment, (B)2 4h ,( C)4 8h ,( D)7 2h ,( E) 96h and (F) 3 weeks after the start of
the first day of administration.
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sapply the method to the clinical samples were not successful (data
not shown).
The pharmacokinetics and metabolism of IFO determined in the
19 patients studied here are very similar to previous reports in
paediatric patients (Boddy et al, 1993, 1995b; Boos et al, 1995;
Kerbusch et al, 2001b). As has been reported previously, there
were no systematic differences between patients treated with a
continuous infusion compared to fractionated dosing (Boddy et al,
1995b; Boos et al, 1995). Induction of metabolism, detected as a
decrease in plasma IFO concentration during infusion or on
successive days of treatment, was apparent in most patients. This
is accounted for largely by an increase in metabolism to inactive
dechloroethylated metabolites (Boddy et al, 1995a; Kerbusch et al,
2001b,c).
The distribution of TMs seen in the pretreatment PBL samples
indicated that the method used was selective for DNA damage
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scaused by the administration of chemotherapy. One patient, a 19-
year-old smoker, had a slightly shifted distribution of TMs and a
greater number of detectable HD cells. However, increases above
background in both TM distribution and percentage HD were seen
in this patient, as with the other patients studied. Figures 1 and 2
show the evolution of DNA damage, as detected by the COMET
assay, before, during and after IFO administration and Figures 3
and 4 overlay the DNA damage data with plasma concentration–
time curves for individual patients.
In order to understand the relationship between DNA damage
and the systemic pharmacology of IFO, a summary measure of
DNA damage AUCHD was plotted against pharmacokinetic
parameters for IFO and AUC values for its metabolites. The only
significant correlation was found between AUCHD and AUC for
IFO itself, and then only for those patients where IFO was
administered as fractionated infusions over 3 days. This is in
contrast to previous reports on cyclophosphamide, where either
antitumour effect or toxicity has been found to be inversely related
to plasma AUC for the parent drug (or positively correlated to
clearance) (Ayash et al, 1992; Yule et al, 2004). This discrepancy in
the data for these two related drugs, which are thought to share a
common mechanism of action, may relate to the differing
contributions of activating and inactivating pathways of metabo-
lism (Boddy and Yule, 2000). Cyclophosphamide elimination is
largely due to metabolism via the initial 4-hydroxylation of the
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Figure 3 Time course of IFO concentration (solid line) and DNA
damage (dotted line) as detected by the COMET assay in patient 3, who
was treated with a 72h continuous infusion. DNA damage quantified as the
percentage of damaged cells in PBL samples.
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Figure 4 Time course of IFO concentration (solid line) and DNA
damage (dotted line) as detected by the COMET assay in patient 18, who
was treated with a 3h infusion on 3 consecutive days. DNA damage
quantified as the percentage of damaged cells in PBL samples.
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Figure 5 Plot of area under the curve for highly damaged cells
(AUCHD) against plasma area under the concentration–time curve for
IFO for those patients who received fractionated infusions over 3 days. Line
indicates regression, with 95% confidence intervals. AUC for IFO in mMh
 1.
AUCHD units are % hours.
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Figure 6 Comparison of summary measure of DNA damage (AUCHD)
according to whether IFO was administered at a dose of 3gm
 2day
 1 by
continuous infusion over 3 days, by fractionated infusions over 3 days or
fractionated infusion over 2 days. AUCHD units are % hours.
Table 3 AUCHD for CCR-CEM cells treated with IPM or 4-hydroxy-
IFO in vitro
Treatment AUCHD
In vitro IPM IC50 13997147
IPM 4 IC50 25497395
4-hydroxy-IFO IC50 28507407
4-hydroxy-IFO 4 IC50 31857819
Clinical data IFO continuous infusion 14537730
IFO 3  daily infusion 27367597
IFO 2  daily infusion 11907419
AUCHD¼area under the curve of % highly damaged cells; IPM¼isophosphoramide
mustard. For comparison, AUCHD data are also shown for patients treated with
either continuous infusion or fractionated dosing of ifosfamide. AUCHD given as
mean7s.d. Units are % hours.
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soxazaphosphorine ring. Only 5% or less of the metabolism of the
parent drug is via the inactivating dechloroethylation pathway
(Moore, 1991). In contrast, 50% of the metabolism of IFO is by
dechloroethylation and up to 23% of a dose is eliminated
unchanged in the urine (Kerbusch et al, 2001a), suggesting that
elimination of parent drug reflects inactivation for IFO. We have
previously reported a weak correlation between DNA damage and
plasma concentrations of the 4-hydroxy metabolite of IFO,
although this unstable metabolite was only measurable in four
patients (Johnstone et al, 2000). The fact that a weak correlation
was seen in the present study between AUCHD and AUC for
carboxy-IFO, which is formed by sequential metabolism of 4-
hydroxy-IFO, may suggest that detection of the carboxy metabolite
in plasma largely reflects activation of the parent drug.
Comparisons of IFO administered either as a 72h continuous
infusion or as a short infusion on 3 consecutive days showed no
consistent difference in the either the metabolism or the clearance
of the parent drug (Boddy et al, 1995b; Boos et al, 1995). Data from
the study reported here, without the within-subject crossover of
previous studies, again indicated no difference in the systemic
pharmacology of IFO between the two schedules. However, there
was a significant difference between the two schedules of
administration with regard to the degree of damage in PBL. The
mean AUCHD was 2497 for the fractionated dosing over 3 days,
whereas that seen following the continuous infusion was 1453. A
lower AUCHD (mean 1190) was observed following 2 days of
fractionated dosing. This difference in pharmacological effect
between the two schedules suggests that the fractionated dosing
schedule may be more effective, perhaps with a greater risk of
toxicity. The mechanism underlying this difference may relate to
changes in enzyme levels during continuous exposure to parent
drug, or might reflect changes in the activity of activating enzymes
following exposure to toxic metabolites. There were insufficient
numbers of patients with consistent treatment in this study to
analyse any relationship to toxicity. Values of AUCHD observed in
PBL in patients were similar to those associated with growth
inhibition in vitro in CCRF-CEM cells.
The data reported here on DNA damage following IFO
administration indicate, in a very heterogeneous patient popula-
tion, that the COMET assay may provide useful information on the
pharmacology of IFO. Fractionating the dose of IFO over 3 days
appears to result in a greater degree of DNA damage than
continuous infusion of the same dose. Also, for patients receiving
IFO as a fractionated schedule, there was a direct correlation
between overall DNA damage and the AUC of the parent drug.
Further studies with patient groups receiving more uniform
treatment should focus on the relationship between DNA damage
and clinical outcome, and also incorporate measures of DNA
crosslink formation (Hartley et al, 1999), in addition to the strand
breaks as detected here. Clinical use of COMET analysis in PBLs
requires further validation by comparison with tumour DNA
damage or clinical outcome.
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